1. Home
  2. INBX

as 12-20-2024 3:38pm EST

$
-
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.

Founded: 2010 Country:
United States
United States
Employees: N/A City: LA JOLLA
Market Cap: 218.9M IPO Year: 2020
Target Price: N/A AVG Volume (30 days): 81.4K
Analyst Decision: Hold Number of Analysts: 1
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: 119.38 EPS Growth: N/A
52 Week Low/High: $10.80 - $18.95 Next Earning Date: 11-14-2024
Revenue: $1,568,000 Revenue Growth: 19.24%
Revenue Growth (this year): -93.76% Revenue Growth (next year): N/A

INBX Daily Stock ML Predictions

Share on Social Networks: